JNJ

Johnson & Johnson Healthcare - Pharmaceuticals Investor Relations →

NO
48.3% ABOVE
↓ Approaching Was 52.6% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $158.68
14-Week RSI 68
Rel. Volume (14w) This week's trading vs. the 14-week average 1.5x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.99

Johnson & Johnson (JNJ) closed at $235.37 as of 2026-03-20, trading 48.3% above its 200-week moving average of $158.68. The stock is currently moving closer to the line, down from 52.6% last week. The 14-week RSI sits at 68, indicating neutral momentum.

Trading volume is running at 1.5x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.99 ratio) is neutral — neither side is clearly dominating.

Over the past 3302 weeks of data, JNJ has crossed below its 200-week moving average 33 times. On average, these episodes lasted 14 weeks. Historically, investors who bought JNJ at the start of these episodes saw an average one-year return of +21.9%.

With a market cap of $567.2 billion, JNJ is a large-cap stock. The company generates a free cash flow yield of 2.9%. Return on equity stands at 35.0%, indicating strong profitability. The stock trades at 7.0x book value.

JNJ is a Dividend Aristocrat, having increased its dividend for 25 or more consecutive years. The current yield is 221.00%. The company has been aggressively buying back shares, reducing its share count by 7.9% over the past three years.

Over the past 33.2 years, a hypothetical investment of $100 in JNJ would have grown to $4781, compared to $2683 for the S&P 500. That represents an annualized return of 12.3% vs 10.4% for the index — confirming JNJ as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 4% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: JNJ vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After JNJ Crosses Below the Line?

Across 22 historical episodes, buying JNJ when it crossed below its 200-week moving average produced an average return of +22.2% after 12 months (median +25.0%), compared to +13.4% for the S&P 500 over the same periods. 85% of those episodes were profitable after one year. After 24 months, the average return was +46.5% vs +29.8% for the index.

Each line shows $100 invested at the moment JNJ crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

JNJ has crossed below its 200-week MA 33 times with an average 1-year return of +21.9% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Dec 1962Jan 196378.4%+39.7%+495655.8%
Feb 1963Mar 196321.1%+44.9%+462675.8%
Apr 1963Apr 196310.3%+36.0%+462675.8%
Jul 1974May 197820130.3%-8.7%+37993.1%
Oct 1978Nov 197855.5%-12.1%+45716.5%
Dec 1978Aug 19793511.8%+4.9%+46592.6%
Oct 1979Nov 197979.9%+22.5%+49758.2%
Feb 1980Apr 198086.4%+42.1%+48194.1%
Feb 1984Apr 198487.8%+13.4%+29325.0%
Apr 1984Jan 19853622.4%+25.7%+27905.8%
Jan 1985Jan 198510.4%+39.5%+26984.2%
Apr 1993Apr 199310.2%-0.5%+5335.8%
Jul 1993Aug 199358.2%+14.4%+5201.0%
Sep 1993Oct 199352.9%+32.0%+5231.2%
Feb 1994May 19941110.2%+44.0%+4923.7%
Mar 2000Apr 200011.2%+26.2%+1221.9%
Jul 2002Jul 2002112.6%+28.0%+976.6%
Jul 2003Aug 200310.1%+11.7%+779.7%
Aug 2003Sep 200321.5%+17.4%+791.3%
Sep 2003Nov 200383.3%+18.6%+777.6%
Nov 2003Dec 200342.5%+25.0%+791.4%
Jan 2004Jan 200410.8%+26.7%+771.0%
Mar 2004Apr 200452.5%+35.9%+762.8%
Oct 2008Jul 20094019.9%+14.3%+606.6%
May 2010Jun 201051.8%+18.7%+544.6%
Jul 2010Aug 201062.2%+20.0%+546.2%
Mar 2020Mar 202023.6%+37.1%+132.2%
Oct 2023Nov 202365.3%+11.3%+65.8%
Apr 2024Jul 2024155.5%+3.8%+63.8%
Nov 2024Feb 2025148.0%+23.9%+58.1%
Mar 2025Apr 202521.3%N/A+57.9%
May 2025May 202521.6%N/A+59.9%
Jun 2025Jun 202521.8%N/A+60.1%
Average14+21.9%

Frequently Asked Questions

Is JNJ below its 200-week moving average?

No. Johnson & Johnson (JNJ) is currently 48.3% above its 200-week moving average of $158.68. It would need to fall to $158.68 to cross below the line.

What is JNJ's 200-week moving average price?

Johnson & Johnson's 200-week moving average is $158.68 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when JNJ drops below its 200-week moving average?

JNJ has crossed below its 200-week moving average 33 times in our data. On average, buying at that moment produced a one-year return of +21.9%. These dips have historically been decent entry points. These episodes lasted 14 weeks on average.

Is JNJ a good value right now?

Here's what our data says about JNJ as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 68. Free cash flow yield is 2.9%. Return on equity is 35.0%. Price-to-book is 7.0x. This is not a buy or sell recommendation — always do your own research.

How does JNJ compare to the S&P 500?

Over the past 33.2 years, $100 invested in JNJ would have grown to $4781, compared to $2683 for the S&P 500. That's 12.3% annualized vs 10.4% for the index. JNJ has outperformed the broader market over this period.

Does JNJ pay a dividend?

Yes. Johnson & Johnson currently pays a dividend yield of 221.00%. It is also a Dividend Aristocrat, meaning it has raised its dividend for 25 or more consecutive years.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20